ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

摘要: Purpose To compare doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) versus etoposide, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) lomustine, vindesine, melphalan, prednisone, epidoxirubicin, bleomycin (COPPEBVCAD; CEC) for advanced Hodgkin's lymphoma (HL). Patients Methods Three hundred seven patients with HL (stage IIB, III, IV) were randomly assigned to receive six courses of ABVD, four escalated plus two standard BEACOPP, or CEC, a limited radiation therapy program. Results After median follow-up 41 months, BEACOPP resulted in superior progression-free survival (PFS), significant reduction risk progression (hazard ratio [HR] = 0.50) compared ABVD. No differences between CEC ABVD observed. The 5-year PFS was 68% (95% CI, 56% 78%), 81% 70% 89%), 78% 68%...